Truist Securities Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Truist Securities maintains a Buy rating on CRISPR Therapeutics but lowers the price target from $120 to $100.
August 12, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on CRISPR Therapeutics but lowers the price target from $120 to $100.
The Buy rating suggests continued confidence in CRISPR Therapeutics' long-term potential, but the lowered price target indicates some caution about short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100